Phase 2
N=387
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
Chronic Myeloid Leukemia · Philadelphia-Positive Myeloid Leukemia
Bottom Line
View on ClinicalTrials.gov: NCT00101660 ↗Enrolled (actual)
387
Serious AEs
50.1%
Results posted
Feb 2010
Primary outcome: Primary: Number of Imatinib-resistant Participants With Major Cytogenetic Response (MCyR) — 159 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Dasatinib (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Bristol-Myers Squibb
- Primary completion
- Sep 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Imatinib-resistant Participants With Major Cytogenetic Response (MCyR) |
159 | — |
| SECONDARY Number of Imatinib-intolerant Participants With MCyR |
81 | — |
| SECONDARY Percentage of Participants Who Achieved MCyR and Did Not Progress at 12 and 24 Months |
98.5; 96.7; 93.7; 83.6 | — |
| SECONDARY Median Time From First Dosing Date to Date of MCyR |
2.79; 2.92 | — |
| SECONDARY Number of Participants With Complete Hematologic Response (CHR) |
93; 259 | — |
| SECONDARY Percentage of Participants Who Acheived CHR and Did Not Progress at 12 Months and 24 Months |
97.7; 93.5; 90.4; 78.8 | — |
| SECONDARY Median Time From First Dosing Until CHR |
0.49; 0.53 | — |
| SECONDARY Number of Participants With Major Molecular Response (MMR) |
73; 102 | — |
| SECONDARY Minimal Clinically Significant Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire Scores |
34; 36; 33; 40; 32; 107 | — |
| SECONDARY Number of Imitanib-intolerant Participants With Drug-related Adverse Events (AEs), Death Within 30 Days of Last Dose, Death, and AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Grade 3-4 Thrombocytopenia, Grade 4-4 Neutropenia, and Any AE |
97; 0; 0; 16; 48; 32 | — |
| SECONDARY Number of Imitanib-resistant Participants With Drug-related AEs, Death Within 30 Days of Last Dose, Death, AEs Leading to Discontinuation, SAEs, Grade 3-4 Thrombocytopenia, Grade 3-4 Neutropenia, and Any AE |
281; 8; 19; 53; 146; 156 | — |
| SECONDARY Blood Sample Collection for Pharmacokinetic (PK) Analysis of Dasatinib |
— | — |
Summary
The purpose of this study is assess the effects of the investigational drug dasatinib on participants who are in chronic phase Philadelphia chromosome chronic myeloid leukemia and who are either resistant to or intolerant of imatinib. Other purposes of the study are to identify any side effects the drug may produce and to study the level of dasatanib in the blood and assess the efficacy of dasatanib in the treatment of leukemia.
Eligibility Criteria
Inclusion Criteria
- Age of 18 years and older.
- Chronic myeloid leukemia (CML)
- Previous treatment with imatinib at a dose of >600 mg/day AND the development of progressive disease while receiving imatinib at that dose, OR
- CML with resistance to imatinib at a dose less than or equal to 600 mg/day with genetic mutation in the BCR-ABL gene that is associated with a high level of resistance to imatinib, OR
- Intolerance to imatinib at any dose
- Adequate organ function
- Women who are able to bear children must have a negative serum or urine pregnancy test. Adequate methods of contraception must be used throughout the study to avoid pregnancy for the entire interval of at least 1 month before and 3 months after completion of the study medication.
Exclusion Criteria
- Woman who are pregnant or breastfeeding
- Men whose sexual partners are women who are of childbearing potential, and who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period as outlined above
- Previous diagnosis of accelerated phase or blast crisis CML.
- Participants who are eligible and willing to undergo transplantation during the screening period
- Uncontrolled or significant cardiovascular disease
- Use of imatinib within 7 days.
- Use of interferon or cytarabine within 14 days
- Use of a targeted small-molecule anticancer agent within 14 days
- Use of certain medication that carry a known side effect risk of Torsade de Pointes - Certain medications that irreversibly inhibit platelet function or anticoagulants
- Prior therapy with dasatinib.
Data sourced from ClinicalTrials.gov (NCT00101660). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.